A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

Authors
Category Primary study
Registry of TrialsJapan Primary Registry Network
Year 2024
This article has no abstract
Epistemonikos ID: 53e23772aa902dc66e8c9ed0ad2e251a1c99378d
First added on: Apr 11, 2025